Merck, Moderna declare Phase 3 success for personalized mRNA cancer vaccine
The next generation of immunotherapy appears to have arrived. Merck and Moderna on Wednesday said their personalized cancer vaccine, known as intismeran autogene, succeeded in its first Phase 3 trial that tested the program in ...
Merck and Moderna have announced that their personalized mRNA cancer vaccine, intismeran autogene, has succeeded in its first Phase 3 trial. The vaccine was tested in combination with Merck's Keytruda in adjuvant melanoma, where patients' disease had been surgically removed.
The trial found that the vaccine slowed the return of melanoma and its spread to other parts of the body. According to STAT News, this is the first randomized Phase 3 clinical trial aimed at proving the benefit of so-called "neoantigen" vaccines as cancer treatments.
The results could potentially deliver new hope and longer lives for patients, and may be a testament to the power of mRNA as a platform to develop cancer treatments. Detailed data from the trial has not been released.
Brief written by urgent.news from Endpoints News, STAT News — 2 reports on this story. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial statnews.com
- Moderna and Merck's personalized skin cancer vaccine cleared its first large-scale trial qz.com
- Personalized cancer vaccine from Moderna, Merck shows promise in first late-stage melanoma trial cnbc.com
